Polymer Capital Management HK LTD Invests $3 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Polymer Capital Management HK LTD bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 36,800 shares of the biotechnology company’s stock, valued at approximately $3,000,000.

Several other hedge funds have also made changes to their positions in ARWR. Versant Capital Management Inc grew its stake in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $25,000. Optiver Holding B.V. increased its stake in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $39,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $87.11 on Monday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $20.44 and a fifty-two week high of $95.49. The firm has a market capitalization of $12.27 billion, a P/E ratio of -38.72 and a beta of 1.27. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The company’s 50 day simple moving average is $82.84 and its 200 day simple moving average is $72.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals’s revenue was up 171.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.26) EPS. On average, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Insiders Place Their Bets

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Piper Sandler reiterated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. B. Riley Financial upped their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Morgan Stanley raised their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.